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Abstract 
Obesity and type 2 diabetes (T2D) are associated with poor tissue responses to insulin1,2, 
disturbances in glucose and lipid fluxes3-5 and comorbidities including steatohepatitis6 and 
cardiovascular disease7,8.  Despite extensive efforts at prevention and treatment9,10, 
diabetes afflicts over 400 million people worldwide11. Whole body metabolism is regulated 
by adipose tissue depots12-14 , which include both lipid-storing white adipocytes and less 
abundant “brown” and “brite/beige” adipocytes that express thermogenic uncoupling 
protein UCP1 and secrete factors favorable to metabolic health15-18. Application of 
clustered regularly interspaced short palindromic repeats (CRISPR) gene editing19,20 to 
enhance “browning” of white adipose tissue is an attractive therapeutic approach to T2D. 
However, the problems of cell-selective delivery, immunogenicity of CRISPR reagents 
and long term stability of the modified adipocytes are formidable. To overcome these 
issues, we developed methods that deliver complexes of SpyCas9 protein and sgRNA ex 
vivo to disrupt the thermogenesis suppressor gene NRIP121,22 with near 100% efficiency 
in human or mouse adipocytes. NRIP1 gene disruption at discrete loci strongly ablated 
NRIP1 protein and upregulated expression of UCP1 and beneficial secreted factors, while 
residual Cas9 protein and sgRNA were rapidly degraded. Implantation of the CRISPR-
enhanced human or mouse brown-like adipocytes into high fat diet fed mice decreased 
adiposity and liver triglycerides while enhancing glucose tolerance compared to mice 
implanted with unmodified adipocytes. These findings advance a therapeutic strategy to 
improve metabolic homeostasis through CRISPR-based genetic modification of human 
adipocytes without exposure of the recipient to immunogenic Cas9 or delivery vectors.  
_____________________________________________________________________  
 
 
The use of human cells as therapeutics offers major advantages over small molecule 
drugs and biologics in treating certain diseases based on their abilities to home to specific 
organs or cell types, initiate cell-cell interactions and secrete multiple bioactive 
factors23,24. Although still in early stages of development, cellular therapies have already 
had major impact on treatment of certain forms of cancer such as leukemia, lymphoma, 
melanoma and small cell lung carcinoma25,26. This approach involves genetic modification 
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ex vivo of immune cells taken from a human subject to enhance their ability to disrupt 
malignancies upon infusion back into the same subject.  In theory, this strategy should be 
effective in diseases in which cells with relevant therapeutic potential can be genetically 
modified to enhance that potential.  Here we take advantage of recent discoveries 
revealing the utility of thermogenic adipocytes to function as major beneficial regulators 
of whole body metabolism in such metabolic diseases as type 2 diabetes and obesity15-
18. Thermogenic adipocytes, denoted as brown27, beige28  or brite27,29, are distinct from 
the more abundant lipid storing white adipocytes not only by their high oxidative capacity 
and expression of mitochondrial uncoupling protein (UCP1) but also by their secretion of 
factors that enhance energy metabolism and energy expenditure15-18.   Multiple studies 
have demonstrated that implantation of mouse brown adipose tissue into obese, glucose 
intolerant mice can improve glucose tolerance and insulin sensitivity30-32. Recently, 
human beige adipocytes expanded from small samples of subcutaneous adipose tissue 
were shown to form robust thermogenic adipose tissue depots upon implantation into 
immune-compromised obese mice and to lower blood glucose levels33. Collectively, these 
data provide the framework to apply genetic modifications to adipocytes to further improve 
their therapeutic potential.  
 
SpyCas9/sgRNA RNPs for ex vivo gene editing   
In order to enhance the therapeutic potential of adipocytes in obesity and diabetes, we 
initially targeted the mouse Nrip1 gene. Nrip1 had been previously shown to strongly 
suppress glucose transport, fatty acid oxidation, mitochondrial respiration, uncoupling 
protein 1 (UCP1) expression as well as secretion of such metabolically beneficial factors 
including neuroregulin 421,22,34.  NRIP1 functions as a transcriptional co-repressor that 
attenuates activity of multiple nuclear receptors involved in energy metabolism, including 
estrogen related receptor (ERRa), peroxisome proliferator activated receptor 
(PPARg) and thyroid hormone receptor (TH)35. NRIP1 knockout in white adipocytes 
upregulates genes that are highly expressed in brown adipocytes, enhancing glucose and 
fatty acid utilization and generating heat. Nrip1 ablation in mice elicits a lean phenotype 
under high fat diet conditions, and greatly enhances energy expenditure, glucose 
tolerance and insulin sensitivity21. However, NRIP1 is not an attractive target for 
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conventional pharmacological intervention as it is not an enzyme and has a multiplicity of 
tissue specific roles such as regulating the estrogen receptor in the reproductive tract35. 
Targeting NRIP1 selectively within adipocytes represents an ideal approach to capture 
its therapeutic potential without undesirable side effects.  
 
A key aspect of our strategy in targeting the Nrip1 gene was to employ methods that 
would ablate its expression in adipocytes but not cause immune responses upon 
implantation of the cells. CRISPR-based methods based on continuous expression of 
Cas9/sgRNA to modify adipocytes that function in vivo have been reported36,37, but they 
expose recipients to Cas9 and delivery agents that cause immune responses. Direct 
administration of Cas9/sgRNA complexes in mice have not been adipocyte-specific and 
could cause undesirable effects in other tissues36. Ribonucleoprotein complexes of 
SpyCas9/sgRNA are desirable vehicles for such modifications since they are rapidly 
degraded following DNA disruption38. A previous attempt at delivery of such CRISPR-
based complexes to adipocytes were suboptimal as efficiencies of delivery of RNPs to 
these cells was only modest34.  We overcame these deficiencies by disrupting Nrip1 in 
mouse preadipocytes with ribonucleoprotein (RNP) complexes of Cas9 and sgRNA by 
modifying electroporation methods39 described for other cell types (Extended Data Fig 1), 
and confirmed Cas9 protein is rapidly degraded following indel formation in 
preadipocytes(Extended Data Fig. 2).  Electroporation conditions were developed to 
optimize the efficiency of Nrip1 gene targeting in mouse preadipocytes by Cas9/sgRNA 
RNPs without perturbing their differentiation into adipocytes (Fig. 1a,b  and Extended 
Data Fig. 1).  
 
The efficiencies of indel formation by 7 different sgRNAs against various regions of Nrip1 
gene exon 4 (Fig. 1a) were uniformly sustained in the 90% range in preadipocytes and 
upon their differentiation into adipocytes (Fig. 1b,c). Indels were quantified by Sanger 
sequencing data analysis of PCR fragments spanning the upstream and downstream 
double stranded breaks of the Nrip1 genomic DNA (Fig. 1c,d) with little change in the total  
Nrip1 mRNAs(Fig 1e). High frequencies of frameshift mutations in Nrip1 by all 7 sgRNAs 
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were found and similar indels were found in the corresponding Nrip1 mRNA species, as 
exemplified by sgRNA M3 and M4 (Extended Data Fig. 3).  
 
While the mRNA of Nrip1 was equally abundant in all groups, indicating no increased 
degradation due to disruption (Fig. 1e), surprisingly, not all of the sgRNAs were effective 
in eliciting loss of the NRIP1 protein (Fig. 1f) . Consistent with these data, thermogenic 
responses to the various sgRNAs as reflected by elevated expression of UCP1 mRNA 
(Fig. 1g) and protein (Fig. 1h) correlated with the loss of native full length NRIP1 protein. 
Taken together, these data show that sgRNAs targeting the regions of Nrip1 DNA that 
encode the N-terminal region of the NRIP1 protein are not effective in eliminating 
synthesis of functional NRIP1 protein. Most likely, additional transcription or translation 
start sites beyond these target sites are functional under these conditions. Thus, sgRNAs 
that are optimal for inducing thermogenic genes must be identified by such screening 
methods.  
 
Implantation of CRISPR-modfied mouse adipocytes 
To test the ability of NRIP1-deficient adipocytes to improve metabolism in mice, large 
numbers of primary preadipocytes obtained from 2-3 week old mice were electroporated 
with RNPs consisting of either SpyCas9/non targeting control (NTC) sgRNA or 
SpyCas9/sgRNA-M6 complexes, and then differentiated into adipocytes and implantated 
into wild type mice. The implanted mice were kept on normal diet for 6 weeks during the 
development of adipose tissue depots from the injected adipocytes, then placed on a high 
fat diet (HFD) regimen to enhance weight gain (Fig. 2a). Adipocytes treated with 
Cas9/sgRNA-M6 displayed upregulation of Ucp1 and other genes highly expressed in 
brown adipocytes (e.g., Cidea) prior to transplantation (Extended Data Fig. 4).  A transient 
decrease in overall body weights were detected between mice implanted with RNPs 
containing the Cas9/sgRNA-M6 versus the Cas9/NTCsgRNA group, but by 6 weeks of 
HFD no significant difference was observed (Fig. 2b). Nonetheless, implantation of 
NRIP1KO adipocytes prevented the increase in fasting blood glucose concentration due 
to HFD that occurs in the control adipocyte-implanted mice (Fig. 2c). Glucose tolerance 
was also significantly improved by implantation of NRIP1KO adipocytes (Fig 2d,e). The 
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implanted adipose tissue depots retained their elevated expression of UCP1 16 weeks 
after implantation, at which time they were excised for analysis (Fig. 2f). The livers and 
inguinal white adipose tissues (iWAT) from the Cas9/sgRNA-M6 group of mice had lower 
weights (Fig. 2g) and lower iWAT to body weight ratios (Extended Data Fig. 4), revealing 
a strong systemic effect.  
 
Livers of the NRIP1 deficient adipocyte-implanted mice were less pale (Fig. 2h), were 
smaller as assessed by lower liver to body weight ratios (Fig. 2i) and displayed lower 
expression of genes associated with fat metabolism (CD36) and with inflammation (Mcp1, 
Tnfa, Il1b) (Fig. 2j) compared to mice implanted with control adipocytes. Lipid droplets in 
the livers of mice with implants of Cas9/sgRNA-M6-treated adiocytes (Fig. 2k) were 
greatly decreased as assessed by quantification of lipid droplet area (Fig. 2l), size and 
number (Extended Data Fig. 4) as well as liver triglyceride determination (Fig. 2m). The 
decrease in hepatic lipid accumulation and inflammation in response to implantation of 
the NRIP1 depleted adipocytes suggests that this therapeutic approach might mitigate 
these T2D co-morbidities in humans6.  
 
Translation to human adipocytes 
To translate these CRISPR-based methods to human adipocytes, adipocyte progenitors 
were obtrained from small samples of excised subcutaneous adipose tissue as previously 
described33. Electroporation conditions were tested to optimize efficiency of indel 
formation using various sgRNAs directed against regions of the NRIP1 exon 4 at locations 
roughly similar to those we targeted in the mouse genomic DNA (compare Fig. 1a to Fig. 
3a). Efficiencies of NRIP1 gene disruption were observed with several sgRNAs in the 
90% range (Fig. 3b), with indel distributions very similar in preadipocytes and adipocytes 
(Fig. 3c).  Electroporated, NRIP1 deficient human preadipocytes could be readily 
differentiated to adipocytes without apparent disruption following indel formation (Fig. 3d). 
NRIP1 mRNA was equally abundant in all conditions (Fig. 3e). UCP1 expression 
increased by up to 100 fold in several experiments in Cas9/sgRNA treated cells, but only 
with certain sgRNAs (Fig. 3f,g), similar to our results with mouse adipocytes. Functional 
NRIP1 protein can still be expressed despite high efficiency indel formation in the N-
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terminal region. NRIP1 disruption in combination with the adenylate cyclase activator 
forskolin synergistically increased UCP1 expression (Fig. 3h).  
 
To test the efficacy of NRIP1-depleted human adipocytes to provide metabolic benefits in 
obese glucose intolerant mice, we utilized immune-compromised NOD.Cg-
Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice that lack T cells, B cells and natural killer cells to 
accept human cell implants in the protocol depicted (Fig. 4a,b). NRIP1 gene disruption 
was about 80% with the sgRNA-H5 (Fig 4c) and circulating human adiponectin (Fig. 4d) 
was the same from NTC vs sgRNA-H5 groups, indicating similar levels of adipose tissue 
formation.  NRIP1KO adipocytes exhibited upregulation of UCP1 levels similar to Fig. 3 
(not illustrated). and the resulting NRIP1KO adipose tissue implants harvested from the 
mice 13 weeks later retained the enhanced UCP1 expression (not shown).  
 
While no body weight difference between groups was detected on normal diet, a highly 
significant decrease in weight gain on the HFD was observed in mice implanted with 
NRIP1 disrupted adipocytes (Fig. 4e). Importantly, mice with control human adipocyte 
implants displayed significantly decreased glucose tolerance 3 weeks after starting a HFD 
while animals with NRIP1-depleted adipocyte implants did not (Fig. 4f-i). The difference 
in glucose tolerance between the two groups at the end of the study was highly 
significant(Fig. 4h,i). Relative liver to body weight ratios (Fig 4j) and liver triglycerides (Fig. 
4k) were also decreased when implants were performed with NRIP1 deficient adipocytes 
compared to control adipocytes.  
 
Taken together, the data presented here show that CRISPR-based RNPs can enhance 
“browning” of adipocytes ex vivo at high efficiency without the use of expression vectors 
to improve metabolic parameters in two mouse models of obesity. Although CRISPR-
based upregulation of UCP1 alone in implanted adipocytes can improve metabolism in 
mice37, targeting NRIP1 has the advantage of upregulating expression of many genes 
that have favorable metabolic effects in addition to UCP1.  The specific approach 
presented here has several additional advantages, including the rapid electroporation 
procedure with minimal loss of viability, the fact that NRIP1 deletion does not diminish 
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adipose differentiation, and the lack of immunogenic Cas9/sgRNA complexes in 
implanted cells. Also, the brief exposure of cells to Cas9/sgRNA that we document here 
(Extended Fig. 2) reduces the potential for off target effects that are produced by long 
term expression of these reagents.   Since UCP1 expression in NRIP1KO adipocytes 
does not reach the level of mouse BAT, our approach can be improved by further 
enhancing adipocyte browning through disrupting combinations of targets in addition to 
NRIP1. Indeed we find that simultaneous delivery of multiple sgRNAs into preadipocytes 
each yield high efficiencies of indel formation (not shown), offering the potential for 
disrupting multiple thermogenic suppressor genes to achieve greater therapeutic 
potential. Also the use of high fidelity nucleases40,41 can further maximize cell viability and 
functionality. Further experiments to define the dose of implanted cells and preferential 
recipient sites will also help optimize this technique as a step towards testing in larger 
animals and advancement towards clinical trials.  
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Figure Legends: 
Figure 1. High efficiency Nrip1 gene disruption at 7 loci by SpyCas9/sgRNA RNPs 
produces variable degrees of NRIP1 protein loss and UCP1 upregulation in murine 
primary adipocytes. a. Mapping of the sgRNAs M1-M7 targeting various loci of murine 
Nrip1 coding region which is entirely located in exon 4 (TSS= transcription start site; 
STOP = stop codon). b. Editing efficiency as evaluated with indel percentage 72 hours 
after the transfection of primary preadipocytes (blue) and differentiation to mature primary 
adipocytes (orange). c. Indel distribution of Nrip1 sgRNA-M6 with frameshift indels that 
are sustained after differentiation. d. Sanger sequencing traces of control vs Nrip1 
disrupted cells with sgRNA-M6 showing the sgRNA binding site (solid black line), PAM 
(red), the double-strand-break (denoted as DSB) site (dashed black line) on the sgRNA-
M6 targeting locus and the traces downstream of the DSB created by the DNA repair 
mechanisms (figure created with SnapGene). e. Nrip1 gene expression detected by RT-
PCR in mature adipocytes targeted with the different sgRNAs. f. Immunoprecipitation 
assay for NRIP1 (140 kDa, arrows at right) in mature primary adipocytes on day 6 post 
differentiation targeted with the different sgRNAs. The total lysate protein amount used in 
the assay was 250 μg per sample. g. Ucp1 expression by RT-PCR in mature adipocytes 
targeted with the different sgRNAs compared to non-targeted control cells. h. Western 
blot for UCP1 protein (33kDa) in mature adipocytes on day 6 post differentiation targeted 
with the different sgRNAs. Lanes 1-8 were loaded with 20 μg of total protein while lane 9 
was loaded with 5 μg οf total protein isolated from mouse BAT. 
NTC = Non-targeting control. In panels b and c error bars denote Mean ± S.E.M. In panels 
e and g, bars denote mean, error bars denote mean ± standard deviations, n ≥ 3 biological 
replicates. 
 
Figure 2.  Implantation of NRIP1-depleted mouse adipocytes improves glucose 
tolerance and markedly decreases iWAT weight and liver triglyceride accumulation 
in recipient mice. Mice were implanted with either mouse adipocytes previously treated 
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with NTC sgRNA/Cas9 RNPs or with sgRNA-M6/Cas9 RNPs (NRIP1KO). a. Schematic 
protocol of implantation of murine NTC adipocytes or NRIP1KO adipocytes into C57BL/6 
wild type mice followed by 60% kCal fat diet (HFD). b. Total body weights of recipients 
on chow after implantation and after 3, 6 and 9 weeks on HFD. c. Fasting blood glucose 
concentrations at 12 weeks post implantation (6 weeks after start of HFD).  d. Glucose 
tolerance test *(GTT) after 16-hour overnight fasting in implant recipients after 6 weeks 
on HFD. e. Bar graphs of areas under the curve from GTTs in implant recipient mice on 
chow and after 6 weeks on HFD. f. Ucp1 expression in the implants harvested after the 
dissection at study termination. g. Weight of total bilateral implants, whole BAT, total 
bilateral iWAT, epiWAT and total liver as measured after dissection. h. Macroscopic 
images of the whole livers of the implant recipients after dissection (square = 1cm2). i. 
Liver over whole body weight percentage. j. Expression of genes related to inflammation 
and involved in hepatic steatosis in the livers of implant recipients detected by RT-PCR. 
k. Hematoxylin and eosin (H&E) stain on liver histology of the implant recipients at 20X 
magnification. l. Quantification of total H&E images of implant recipients’ livers for total 
area occupied by lipid droplets per field. m. Triglyceride measurements in pulverized liver 
extracts after dissection. 
Panel c-e: black = NTC adipocytes; red = NRIP1KO adipocytes, n ≥ 3 biological 
replicates, panels c-e: black = NTC cell implants (n=7) ; red = NRIP1KO cell implants 
(n=8), Panels b,f-m: black = NTC cell implant recipients (n=4) ; red = NRIP1KO cell 
recipients (n=3). Bars represent the mean, error bars denote mean ± standard deviation. 
* p < 0.05, ** p < 0.01, *** p < 0.001 by unpaired two-tailed T-test.  
 
Figure 3. High efficiency NRIP1 disruption in human adipocytes by SpyCas9 
reveals variable UCP1 upregulation in a screen of sgRNAs targeting different loci 
of NRIP1. a. Mapping of sgRNAs H1-H6 screened against human NRIP1 coding region 
entirely located in exon 4. b. Editing efficiency as evaluated with indel percentage 72 
hours after the transfection of primary preadipocytes (blue) and differentiation to mature 
primary adipocytes (orange). c. Indel distribution of NRIP1 sgRNA-H5 with frameshift 
indels that are sustained after differentiation. d. Microscopic image of cell culture of non-
targeted control (top) and NRIP1 disrupted (bottom) mature adipocyte morphology in cell 
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culture at 10X magnification. e. NRIP1 gene expression by RT-PCR in mature adipocytes 
on day 7 post differentiation targeted with the different sgRNAs. f. UCP1 expression by 
RT-PCR in mature adipocytes on day 7 post differentiation targeted with the different 
sgRNAs compared to non-targeted control cells. g. Western blot for UCP1 protein 
(33kDa) in mature adipocytes on day 7 post differentiation targeted by the sgRNAs H4 
and H5 with two different electroporation optimization protocols. Lanes 2-6 were loaded 
with 20 μg of total protein while lane 9 was loaded with 2.5 μg οf total protein isolated 
from mouse BAT. h. UCP1 gene expression by RT-PCR in non-targeted control or NRIP1 
depleted adipocytes on day 7 post differentiation after a 7-hour stimulation of forskolin 10 
μM or vehicle. 
NTC = Non-targeting control. Bars denote mean. In panels b and c, error bars denote 
Mean ± S.E.M. In panels e,f and h error bars denote mean ± standard deviations, n ≥ 3 
biological replicates. 
 
Figure 4. Implantation of NRIP1-targeted human adipocytes decreases body weight 
as well as liver triglyceride, and enhances glucose tolerance in recipient 
immunocompromised, HFD fed NSG mice. Mice were implanted with either human 
adipocytes previously treated with NTC sgRNA/Cas9 RNPs or with sgRNA-H5/Cas9 
RNPs (NRIP1KO).   a. Study description: 1) adipose tissue isolation from a human donor 
during panniculectomy, 2) harvesting of human primary preadipocytes after  development 
Cas9/sgRNA RNPs were delivered into the human preadipocytes by electroporation 
followed by 3) expansion 1:6 of the genetically modified preadipocytes and 4) their 
differentiation into mature adipocytes;  5) Implantation of non-targeted control (NTC) 
sgRNA treated adipocytes versus the NRIP1 depleted adipocytes was performed in the 
dorsal area of NSG mice. b. Schematic protocol of implantation of human NTC adipocytes 
or NRIP1KO adipocytes into NSG mice followed by HFD feeding. c. Editing efficiency as 
evaluated with percentage of indels in the mature adipocytes transfected with NRIP1KO 
sgRNA-H5 before implantation (blue) and indel percentage in the genomic DNA isolated 
from the NRIP1 depleted implants 15 weeks following transplantation. d. Human 
adiponectin levels detected in the plasma of NSG recipients 9 weeks following 
transplantation for the assessment of engraftment and functionality of the implants. e. 
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Total body weight of NSG mouse recipients before transplantation (left) and after 3 weeks 
on HFD and thermoneutrality (right). f. Baseline glucose tolerance test after 16 hr fasting 
before transplantation. g. Glucose tolerance test after 3 weeks on HFD and 
thermoneutrality. h. Glucose tolerance test areas under the curve (GTT AUC) before 
transplantations (left) and 3 weeks after HFD under thermoneutrality (right). i. Matched 
difference of the GTT AUC before transplantations (left) and 3 weeks after HFD and 
thermoneutrality (right). j. Liver over whole body weight percentage. k. Triglyceride 
measurements in pulverized liver extracts after dissection.  
Black = NTC cell implant recipients (n=4) ; red = NRIP1KO cell implant recipients (n=6) 
Bars denote mean, error bars denote mean ± standard deviation. * p < 0.05, ** p < 0.01 
by unpaired T-test. 
 
Extended data  
Extended Data Figure 1. SpyCas9/sgRNA RNPs are more efficiently delivered into 
murine adipocytes by electroporation than plasmid expression.  Delivery of 
SpyCas9/sgRNA RNPs versus plasmids encoding either GFP or Cas9 and sgRNA 
electroporated with preadipocytes were compared. a. GFP expression plasmid (Lonza 
pmaxGFP) was used in various concentrations for optimization of the plasmid delivery by 
electroporation in murine preadipocytes (data not shown) to determine the optimum range 
(0.1-0.2 pmols) that induces GFP expression by fluorescent microscopy (white line = 400 
μm). Top: Control preadipocytes Bottom: Preadipocytes transfected with 0.2 pmols at 72 
hours after electroporation (1350 V, 30 ms, 1 pulse). b. Application of the optimized 
electroporation protocol to transfect preadipocytes with plasmids expressing SpyCas9 
and sgRNA-M6 in three different concentrations within the range determined with the GFP 
plasmid titration: 0.1 - 0.3 pmols. c. Optimization of the electroporation protocol to deliver 
CRISPR RNPs in preadipocytes with 1 pulse and 30ms width and increasing voltage. d. 
Titration of RNP concentrations in correlation with the editing efficiency with sgRNA-M6. 
e. Mature adipocytes transfected before differentiation with either NTC RNPs or sgRNA-
M6 in cell culture and magnification 10X. f. Nrip1 gene expression by RT-PCR in mature 
adipocytes transfected with varying RNP concentrations. g. Ucp1 gene expression by RT-
PCR in mature adipocytes transfected with varying RNP concentrations. h. UCP1 
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expression by western blot in mature adipocytes transfected with various RNP 
concentrations. 
NTC = Non-targeting control. Bars denote mean. In figures c, d error bars denote Mean 
± S.E.M. In panels f, g error bars denote mean ± standard deviations. n ≥ 3 biological 
replicates. Nrip1 sgRNA-M5 was used in the titration experiment. 
 
Extended Data Figure 2. SpyCas9/sgRNA RNP-mediated Nrip1 disruption in 
preadipocytes is characterized by little or no off-target editing and degradation of 
SpyCas9. a. Editing at the top three predicted off-target loci of the sgRNA-M6 in the 
murine genome by sanger sequencing data analysis. b. Editing at the top three predicted 
off-target loci of the sgRNA-H5 in the human genome by sanger sequencing data 
analysis. c. Time-course SpyCas9 protein detection by Western Blotting in cell lysates at 
various time points after electroporation to deliver RNPs of SpyCas9: sgRNA 30:40 pmols 
( sup 0 hours), in preadipocytes immediately after electroporation (0 hours), in 
preadipocytes at 12, 24, 48 and 72 hours following electroporation and in mature 
adipocytes 11 days after electroporation corresponding to day 6 of differentiation. 
 
Extended data Figure 3. mRNA of Nrip1 harbors the indels created by the CRISPR-
RNPs with little evidence of truncation or degradation of modified Nrip1 mRNAs. a. 
Comparison of the indel distribution of the genomic DNA and the cDNA after double 
rDNAse treatment in the template RNA of cells transfected with sgRNA-M3 and sgRNA-
M4. b. RT-PCR results of the expression of different loci across Nrip1 cDNA as shown in 
the map. c. Top: Nrip1 gene includes 4 exons (black) and the coding region (red) is 
contained in exon 4. Middle: Alignment of the mouse and human coding regions of NRIP1 
that spans 3486bp and 3477bp respectively between the TSS and STOP codons, 
highlighting the site targeted with sgRNAs M1-6 and H1-5 (gray). Bottom: 5’à 3’ DNA 
sequence alignment of the mouse (top strand) and human (bottom strand) of the N-
terminus area targeted with the sgRNAs M1-6 for the mouse (green arrows) and H1-5 for 
the human (orange arrows). Underlined (red) are the ATG sequences in frame or out of 
frame between the TSS and the first sgRNA that depletes Nrip1 which could potentially 
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serve as alternative translation initiation sites. In panel b error bars denote mean ± 
standard deviations. n ≥ 3 biological replicates. 
 
Extended data Fig.4. Characterization of mice implanted with Cas9/NTC sgRNA- 
versus Cas9/sgRNA-M6-treated adipocytes. a. RT-PCR results for expression of 
genes involved in thermogenesis, mitochondrial electron transport chain, lipid and 
glucose metabolism and the neurotrophic factor Nrg4 prior to implantation. b. Baseline 
GTT after 16-hour fasting in the chow-fed recipients before the implantation of adipocytes. 
c. iWAT over whole body weight percentage. d. epiWAT over whole body weight 
percentage. e. Macroscopic images of the whole implants of the recipients after dissection 
(square = 1cm2). f. Editing evaluation of homogenized implant sample for each of the 
NRIP1KO adipocyte recipients. g. Histology images stained with H&E of the implant in 
5X magnification (left) and 20X magnification (right). h. Quantification of the number and 
i. size of lipid droplets in the histology of the livers of the mouse NRIP1KO adipocytes 
recipients. 
Panel a: Black = NTC cell implant recipients (n=7) ; red = NRIP1KO cell implant recipients 
(n=8), Panel b-h: Black = NTC cell implant recipients (n=4) ; red = NRIP1KO cell implant 
recipients (n=3), Bars denote mean, error bars denote mean ± standard deviation. * p < 
0.05, ** p < 0.01 by unpaired two-tailed T-test. 
 
Methods: 
Animals and Diets 
All animal work was approved by the University of Massachusetts Medical School 
Institutional Animal Care Use Committee with adherence to the laws of the United States 
and regulations of the Department of Agriculture. Mice were housed at 20-22 °C on a 12-
hour light/12-hour dark cycle with ad libitum access to food and water.  C57BL/6J male 
mice were purchased from Jackson Laboratory for implant studies.  C57BL/6J (Jackson 
Laboratory) male mice were bred for primary preadipocyte cultures.  Briefly, 10-week old 
male mice arrived and were allowed to acclimate for a week prior to any procedures.  Mice 
were implanted with edited primary mouse adipocytes at 11 weeks of age by 
anesthetizing prior to the implantation procedure using an anesthesia vaporizer chamber 
with a continuous flow 500 cc/minute of 02 with isoflurane 3% for induction and 1.5% for 
maintenance. After the cell injections, animals are allowed to wake up and were placed 
back in clean cages. Mice were maintained on a chow diet for the first 6 weeks, followed 
by a 60 kcal% high fat diet (Research Diets, D12492i) for the remainder of the experiment 
from 6-16 weeks post implant. Glucose tolerance tests were performed after 16-hour 
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overnight fasting with intraperitoneal injection of 1g/kg D(+) glucose. Insulin tolerance 
tests were performed with 0.75IU/kg after 6-hour daytime fasting. Male NOD.Cg-
Prkdcscid Il2rgtm1Wjl/SzJ (denoted as NSG) mice were kindly donated by Taconic 
Biosciences, Inc. NSG mice were implanted with edited primary human adipocytes at 11 
weeks of age.  Mice were maintained on a chow diet for the first 10 weeks, followed by 
placing them at thermoneutral with a 60 kcal% high fat diet (Research Diets, D12492i) for 
the remainder of the experiment from 10 to 15 weeks post implant.  Housing under 
thermoneutrality was achieved by placing the NSG mice at 30°C on a 12-hour light/12-
hour dark cycle.  Glucose tolerance tests with NSG mice were performed after a 16-hour 
fast with intraperitoneal injection 2 g/kg D(+) glucose. Whole blood was drawn and placed 
in EDTA-containing tubes from living mice with submandibular vein punctures under 
anesthesia as described above and in the end of the study with cardiac puncture. Plasma 
was extracted with centrifugation of whole blood for 15 minutes at 300 rcf at 4 oC. 
 
Human Subjects 
Abdominal subcutaneous adipose tissue was obtained from discarded tissue following 
panniculectomy. All subjects consented to the use of tissue and all procedures were 
approved by the University of Massachusetts Institutional Review Board.  
 
 
Primary Mouse Preadipocyte Isolation, Culture and Differentiation to Primary 
Adipocytes 
2 to 3 week old C57BL/6J male mice were euthanized and inguinal fat tissue was 
harvested (including lymph node) and placed in HBSS buffer (Gibco #14025) plus 3% 
(w/v) bovine serum albumin (BSA) (American Bioanalytical).  The protocol was carried 
out as described previously34 with the following modifications; cells were incubated in 2 
mg/mL collagenase (Sigma #C6885) in HBSS BSA 3% (w/v) for 20 minutes to digest the 
tissue.  Cells were cultured to sub-confluence in complete media containing DMEM/F12 
media (Gibco #11330) , 1% (v/v) Penicillin/streptomycin, 10% (v/v) Fetal bovine serum 
(FBS) (Atlanta Biologicals #S11550), 100 μg/mL Normocin (Invivogen #Ant-nr-1) at which 
time they were transfected with RNPs by electroporation and re-plated. Αdipocyte 
differentiation was induced in the edited cells 24 hours post confluence previously 
described34.  Cells grown post differentiation induction were cultured in complete media. 
 
Primary Human Preadipocyte Isolation, Culture and Differentiation to Primary 
Adipocytes 
Explants from human abdominal subcutaneous adipose tissue from individuals 
undergoing panniculectomy surgery were embedded in Matrigel and cultured in as 
previously described33,42. Human adipocyte progenitors were transfected with RNPs by 
electroporation and plated at a density greater than 70% confluence to allow for 
expansion.  Cells were grown to confluence then adipogenic differentiation media was 
added to induce adipogenesis33,42. On day 10 post differentiation, cells were harvested 
for implantation in NSG mice by treating with 0.5 mg/mL collagenase in 1x Trypsin to 
detach from culture plates. 
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Transfection of Primary Preadipocytes (Mouse and Human) with RNPs  
For ribonucleoprotein (RNP) transfection, we used the Neon Transfection System 100 μL 
Kit (ThermoFisher, #MPK10096) and we prepared a mix consisting unless otherwise 
specified of sgRNA 40 pmol (Synthego or IDT DNA) purified SpyCas9 protein 30 pmol 
(PNA Bio, #CP02 or 3xNLS-SpCas943(prepared by the Scot Wolfe laboratory) in Buffer R 
provided in the Neon Transfection System Kit. The cells were resuspended in 
Resuspension Buffer R for a final number of 0.5-6 x106 cells per electroporation.  For 
delivering the RNP complex into primary pre-adipocytes the electroporation parameters 
used were voltage 1350 V, width of pulse 30 ms; number of pulses 1 unless otherwise 
specified. The electroporated cells were placed in complete media immediately following 
transfection, expanded, grown to confluence and differentiated into mature adipocytes for 
downstream applications. We found these methods improved the viability of 
preadipocytes and adipocytes and their ability to differentiate over methods reported while 
our manuscript was in preparation44. 
 
Implantation of Primary Mouse and Human Adipocytes  
Primary mouse and human mature adipocytes on day 6 and 10 post differentiation 
respectively were washed twice with 1xPBS.  0.5 mg/mL collagenase in 1 x trypsin was 
used to dissociate the cells from the plate.  The detached cells are pelleted at 300 rcf for 
10 minutes at room temperature.  The cells were washed with 1xPBS, pelleted, and the 
PBS was removed.  Cell pellets were kept on ice for a brief time until implantation. Each 
mouse adipocyte pellet deriving from 1 x 150 mm fully confluent plate was mixed with  
matrigel (Corning® Matrigel® Growth Factor Reduced Basement Membrane Matrix, 
Phenol Red-free, LDEV-free # 356231) up to a total volume of 500 μL on ice and the cell 
and matrigel suspension (500 ± 20 μL)  was drawn into a 1 mL tuberculin syringe without 
the needle.  The cell and Matrigel mixture was injected into the anesthetized mouse 
recipient with a 20 G needle by tenting the subcutaneous subscapular area, inserting the 
needle into the tented space and injecting at a slow but continuous rate to avoid cell 
rupture and solidification of the matrigel. The injection site was pinched gently for 1 minute 
to allow the implant to solidify, followed by withdrawing the needle with a twisting motion. 
Each C57BL/6J mouse recipient was injected with 2x150mm plates of fully confluent 
murine adipocytes split into two bilateral injections in the subscapular area. Each NSG 
mouse recipient received 1 x 150 mm plate split into two 500 μL bilateral subcutaneous 
injections in the dorsal area as described above.   
 
DNA Harvest from cells and tissue 
At two distinct time-points, 72 hours following transfection and after primary adipocyte 
differentiation between day 6-10 post differentiation, genomic DNA was isolated from the 
transfected cells using DNA QuickExtract™ Buffer (Lucigen) in adherence to the 
manufacturer’s instructions.  
 
Indel analysis by TIDE and ICE  
Genomic DNA was PCR amplified for downstream analysis using locus specific primers 
designed with MacVector 17.0 and purchased from IDT DNA and Genewiz, spanning the 
region  800 bp around the expected DSB. For the PCR, Kappa 2x Hot start HiFi mix was 
used and PCR products were purified using the QIAgen DNA purification kit following the 
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manufacturer’s instructions, and submitted to Genewiz for Sanger Sequencing. Sanger 
sequencing trace data were analyzed with TIDE and ICE webtools 
(http://shinyapps.datacurators.nl/tide/, https://ice.synthego.com/#/) that decipher the 
composition of indels created at the sites of DSBs45,46 .  
 
RNA Isolation 
Transfected cells were harvested for RNA between day 6-10, post-differentiation 
depending on the experiment by removing media and washing once with 1xPBS, and 
adding Trizol reagent to lyse the cells.  The protocol for RNA isolation was performed 
according to manufacturer’s instruction with the following modifications; 1μl of Glycol blue 
(Invitrogen #AM9516) was added to the isopropanol to precipitate the RNA and was either 
stored overnight at -20°C or placed on dry ice for 2 hours.  The isolated RNA was 
resuspended in RNase free water, then treated with recombinant DNaseI (DNA-free DNA 
removal kit, Ambion) according to the manufacturer’s instructions.  RNA concentrations 
were determined by Nanodrop 2000.   
 
RNA Isolation of Pulverized Tissue/Tissue Piece 
Tissue was isolated from the mice and frozen in liquid N2.  For RNA isolation, tissue was 
pulverized in liquid N2, or a piece approx. 100 mg in size was put in a 2 mL tube with 
screw cap and 1mL of Trizol. Tissue was placed in the Qiagen TissueLyser and 
homogenized for 3 cycles of 3 minutes at 30Hz. The Trizol and tissue lysate were placed 
in a new tube, and centrifuged for 10 minutes at 4°C to separate any lipid from the 
homogenate.  Once the homogenate is separated from the lipid, the remaining isolation 
is carried out according to manufacturer’s instructions. 
 
RT-PCR 
0.5-1 μg of RNA was used in 20 μL reaction with Bio-Rad iScript cDNA kit according to 
manufacturer’s protocol to synthesize cDNA.  cDNA was diluted by adding 80 μL of water 
to the reaction and 5 μL of cDNA template was used for RT-PCR with Bio-Rad Sybr Green 
Mix and gene specific primers for a final concentration of 0.3 μM primers.  Expression of 
genes was determined by comparing gene expression levels of target gene compared to 
housekeeping gene 36B4 and RPL4 for murine and human samples respectively. mRNA 
expression was analyzed with the ΔΔCT method. 
 
Protein Isolation 
Cells grown in culture dishes were washed once with 1 x PBS at room temperature, 
followed by adding boiling 2% SDS (w/v) with 1 X HALT protease inhibitors and scraping 
to lyse the cells.  Tissue pieces were prepared for western blots by homogenizing a piece 
approximately 100 mg in Radioimmunoprecipitation Assay (RIPA) buffer with 1x HALT 
protease inhibitors in the Qiagen TissueLyser and homogenized for 3 cycles of 3 minutes 
at 30Hz.  Tissue and cell lysates prepared with 2% SDS (w/v) buffer or RIPA buffer were 
sonicated at 60% amplitude with a probe sonicator tip for 30 seconds at room 
temperature. In figure S2, mouse cells were lysed as described above at different time-
points after transfection and for timepoint 0 hours, after the electroporation the 
transfection mix consisting of cells and RNPs in Buffer R was centrifugated at 300 rcf. 
The cell pellet was lysed as described above while the supernatant (sup) was also 
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collected for use as positive control (30pmols of SpyCas9) in the western blot. Protein 
concentration determination of the tissue and cell lysates was performed using a 
bicinchoninic acid kit (BCA Protein Assay Kit, Pierce).  Cell lysates used in 
immunoprecipitation reaction were prepared in non-denaturing NP-40 buffer (20mM Tris 
HCl pH 8.0, 137mM NaCl, 1% (v/v) Nonident P-40 (NP_40), 2mM EDT) containing 1X 
HALT protease inhibitors by washing once with 1 x PBS, adding NP-40 buffer and 
scraping, followed by a 4 °C incubation for 30 minutes to 1 hour with gentle agitation.  Cell 
lysates were centrifuged at 4 °C for 10 minutes at 16,100 rcf and the infranate was 
collected and used.  Protein concentrations were determined on the lysates using Pierce 
BCA Kit.  Protein samples were prepared for running on 7.5-12 % SDS-PAGE mini gels 
at a final concentration of 1mg/mL protein, 1x Laemmli loading buffer (BioRad) with 2.5 
%(v/v) b-Mercaptoethanol, followed by placing in a heat block at 95 °C for 10 minutes.   
 
Triglyceride Assay  
For the liver triglyceride assay, we used the Triglyceride Colorimetric assay kit (Cayman 
Chemical, #10010303). The lysate was prepared by mixing 50 mg of pulverized whole 
liver with 1.5 mL of the NP-40 lysis buffer and homogenized in the Qiagen TissueLyser 
with 3 cycles 3 minutes at 30 Hz. The assay ran according to manufacturer instructions 
with a sample dilution of 1:5. 
 
Human Adiponectin 
Human adiponectin was measured in the plasma of NSG mice was measured using a 
human-specific adiponectin ELISA from Invitrogen (KHP0041). 
 
Histology 
Approximately 0.5 cm2 of the implant tissue and two 0.5 cm2 liver pieces from two different 
lobes per recipient were randomly selected and fixed, followed by processing at the 
UMass Medical School Morphology Core. Photos of the tissues were taken with an LEICA 
DM 2500 LED inverted microscope at indicated magnification. Fiji/ImageJ was used to 
quantify lipid content in H&E images. 4 images per section, 2 sections per liver, were 
projected into a single montage. The montage was converted from RGB to 8 bit, contrast 
enhanced, thresholded and binarized. The processed montage was reconverted into 
individual images and lipid droplets quantified for each image using the particle analysis 
function (number, size, % of area covered). 
 
 
Western Blotting and Immunoprecipitation 
Protein lysates were run on 7.5 and 12% SDS-PAGE or Mini-Protean TGX stain-free pre-
cast protein gels, followed by transferring the proteins to Nitrocellulose. Unless otherwise 
stated, a total of 20 μg of protein lysate was loaded per well.  Nitrocellulose membranes 
were blocked using 5% (w/v) Non-fat milk in Tris buffered saline with 0.1% (v/v) Tween-
20 (TBST) for 1 hour at room temperature.  Primary antibody incubations were carried 
out in  5% (w/v) BSA in TBST at the following antibody concentrations: UCP1-
Abcam#10983 , 1:700; Rip140-Millipore #MABS1917, 1:1000, Tubulin-Sigma #T5168, 
1:4000; GAPDH-Cell Signaling #21185, 1:1000; SpyCas9-Cell Signaling #19526S 
1:5000. Blots and primary antibodies were incubated overnight with a roller mixer at 4°C.  
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Membranes were washed with TBST prior to secondary antibody incubations.  HRP-
conjugated secondary antibodies were diluted with 5% BSA (w/v) in TBST at 1:5,000-
10,000 for 45 minutes at room temperature with constant shaking.  Membranes were 
washed in TBST, followed by incubating with Perkin Elmer Western Lightning Enhance 
ECL.  The Bio-Rad Chemi-Doc XRS was used to image the chemiluminescence and 
quantifications were performed using the system software, or Image J.  
Immunoprecipitation was performed with NP-40/Halt protein lysates.  Briefly, 250 μg of 
protein lysates were pre-cleared using 50:50 Protein-A Sepharose/NP-40 buffer/1x HALT 
protease inhibitors for 2 hours at 4°C with end over end mixing.  After 2 hours, the 
lysate/Protein A Sepharose was centrifuged for 5 seconds to pellet the Sepharose, and 
the lysate was transferred to a new tube. 5 μg of Antibody (Rabbit Non-Immune IgG, 
Millipore #12-370, or Rabbit anti-Nrip1, Abcam #Ab42126) was added to the lysates and 
they were incubated overnight at 4 °C with end over end mixing.  Antibody/antigen was 
pulled down by adding 50:50 Protein A Sepharose/NP-40 buffer/1x HALT protease 
inhibitors for an additional 2 hours at 4°C with end over end mixing.  
Protein/Antibody/Protein A Sepharose complexes were washed by centrifuging briefly, 
removing the supernatant and washing the pellet with NP-40 buffer containing protease 
inhibitors.  The captured proteins were eluted from the Sepharose by adding 40 μL of 
1xLaemmli buffer containing 2.5% (v/v) β-Mercaptoethanol, vortexing the Sepharose 
mixture, followed by boiling at 95°C for 10 minutes.  All eluted proteins were run on the 
gel, transferred to nitrocellulose, and immunoblotted as described above.   
Plasmid construction 
The pCS2-Dest plasmid with CMV promoter expressing SpyCas9 (Addgene # 69220), 
and sgRNA expressing plasmid (Addgene #52628) were a gift from Dr. Scot Wolfe lab. 
To clone NRIP1 targeting and non-targeting sgRNAs, oligo spacers with BfuAI 
overhangs (purchased from IDT) were annealed and cloned into the BfuAI-
digested sgRNA plasmid. Lonza pmaxGFP LOT 2-00096 was used to test transfection of 
these plasmids in various concentrations to determine the efficient dosage range (0.5–
1.5 μg) and the electroporation conditions (1350 V, 30ms, 1 pulse) for the delivery and 
GFP expression was evaluated with EVOS FL fluorescent microscope (Thermo Fisher 
Scientific).  
 
Statistical analysis 
All comparisons are between two groups and student unpaired two-tailed T-Test was 
performed for the p values. In data that did not follow Gaussian distribution, 
standardization preceded the statistical analysis. * p < 0.05, ** p < 0.01, *** p < 0.001.  
 
Additional online tools and Software 
For the mapping of exons on the Nrip1 gene we used IGV_2.5.3. For the Design of 
sgRNAs we used a combination of the Broad Institute sgRNA designer, CHOPCHOP and 
the online sgRNA checkers by Synthego and IDT. For the design of genomic DNA primers 
we used MacVector 17.0. For the alignment of the Sanger Sequencing traces and the 
human and mouse coding region we used SnapGene Viewer 5.1.6 and NCBI nucleotide 
blast. For the design of RT-PCR primers we used Primer Bank 
(https://pga.mgh.harvard.edu/primerbank/). For the prediction of off-target editing sites, 
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we used Standard nucleotide blast by NCBI to determine the first three potential binding 
sites with a PAM sequence downstream. For the data graphing, we used Prism GraphPad 
8. 
 
Table 1. Sequences of sgRNAs 
Mouse sgRNA sequences (5’à 3’) Human sgRNA sequences (5’à 3’) 
Nrip1 sgRNA-
M1 
CTTGTATTGAACATGAC
TCA 
NRIP1 sgRNA-
H1 
CTTCTATTGAACATGACT
CA 
Nrip1 sgRNA-
M2 
ATTGTCTTAACTTACCT
CGA 
NRIP1 sgRNA-
H2 
GCTTGGCTCTGATGTGC
ACC 
Nrip1 sgRNA-
M3 
GTCAGTACCCAGACGT
ACCA 
NRIP1 sgRNA-
H3 
ACACATACATATCAGGGG
TC 
Nrip1 sgRNA-
M4 
ATAAGGTTTGGAGTCAC
GTC 
NRIP1 sgRNA-
H4 
ACATCAGGAAGATTCGTA
TC 
Nrip1 sgRNA-
M5 
CACTTTGTCCCACTGC
GGGA   
Nrip1 sgRNA-
M6 
ACAGGCTGTTGCCAGC
ATGG 
NRIP1 sgRNA-
H5 
GTCATGTGCTGCAAGATT
AC 
Nrip1 sgRNA-
M7 
GGAGTCGAAGAACATC
TGCA 
NRIP1 sgRNA-
H6 
TTTGCATGGTCCCTAAGA
AA 
Human and Mouse Non targeting control sgRNA (NTC) : GCACTACCAGAGCTAACTCA 
 
Table 2. Primers for genomic DNA PCR and Sanger sequencing (sequencing primers 
bolded) 
Mouse genomic primers (5’à 3’) Human genomic primers (5’à 3’) 
M1-3 Fw1 
CTCATCAGTGCTGTAGTCT
G or 
TGTGCTAAGGAAGTTGCG
AGG 
H1-H2 Fw CTTCTCCTCCTCCTTGCGTA 
M1-3 Fw2 TGTGCTAAGGAAGTTGCGAGG H1-H2 Rv 
CTTGAGGCTCTGCCTGATT
T 
M1-3 Rv AGCCTAGAGCTGAATGACT H3 Fw AGTTACATCGCACTCACC 
M4-6 Fw CTCTAGGCTGCAGACTGTT* H3 Rv GGAGACTCTGCAAACCTAT 
M4-6 Rv CAGTGAGTTCTTATAGCTCG** H4 Fw 
CACCTGTCAAAGTAATGGT
C 
M7 Fw CTTCTTAGGTGTGACTCCC H4 Rv CACTAGGTTTAGGTGAGGTG 
M7 Rv CTATGATCCGTCACACAAC H5 Fw TAGCACATTACTGGCCTC 
M6 OT1 
Fw 
AAAGCCCTGAGTCTACGG
GT H5 Rv 
CACTGTAGCACTACTTTTG
C 
M6 OT1 
Rv 
TTTATGGTTGGGGGATACC
A H6 Fw CTGAGCCTTGTGATGACT 
M6 OT2 
Fw 
TCTGACAACTTCCCTTTCC
C H6 Rv 
TGAGTGGAACTGTACATCA
G 
.CC-BY-NC-ND 4.0 International license(which was not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprintthis version posted October 13, 2020. . https://doi.org/10.1101/2020.10.13.337923doi: bioRxiv preprint 
M6 OT2 
Rv 
TTAGTACAGGGGGCAGGA
TG 
H5 OT1 
Fw 
GATAATTTCCAGAAGCCC
C 
M6 OT3 
Fw 
ATCATAGAAGATGGAGGG
GG 
H5 OT1 
Rv TCTGCAACCTTTTGTAGGG 
M6 OT3 
Rv 
GCTGGAAACTCACCAGAG
GA 
H5 OT2 
Fw 
TTCACCAACAGGAGACTGG
AT 
  H5 OT2 Rv 
CACTTACCACATGACCCA
GC 
  H5 OT3 Fw GGCAGCCAAAGAAGTTTGA 
  H5 OT3 Rv 
AACTTACCCAGCAGTCCTT
G 
OT = off-target; Fw = forward; Rv = reverse, Sequencing primer for *M6, **M4-5 
 
Table 3. RT-PCR Primers 
Speci
es 
Gene 
Name Forward (5’à3’) Reverse (5’à3’) 
Mouse 
36B4 TCCAGGCTTTGGGCATCA CTTTATCAGCTGCACATCACT
CAGA 
Nrip1 AGACCAGAACTTTAACCTCTC
GG 
CGATGGAATCAGACAGCCTC
T 
Ucp1 ACTGCCACACCTCCAGTCATT CTTTGCCTCACTAGGATTGG 
Cidea ATCACAACTGGCCTGGTTACG TACTACCCGGTGTCCATTTCT 
Pgc1
α 
TATGGAGTGACATAGAGTGTG
CT 
CCACTTCAATCCACCCAGAAA
G 
Cox7
a 
GCTCTGGTCCGGTCTTTTAGC GTACTGGGAGGTCATTGTCG
G 
Cox8
b 
TGTGGGGATCTCAGCCATAGT AGTGGGCTAAGACCCATCCT
G 
Pparγ GCTTGGTGCCTTCGCTGA TGGCATCTCTGTGTCAACCAT
G 
Glut4 CAATGGTTGGGAAGGAAAAGG
GCTA 
GTAGGCGCCAATGAGGAACC
GTC 
Pepck
1 
ATGAAGTTTGATGCCCAAGGC
AAC 
GGATTTGTCTTCACTGAGGT
GCC 
Fasn GGAGGTGGTGATAGCCGGTAT TGGGTAATCCATAGAGCCCA
G 
Nrg4 CACGCTGCGAAGAGGTTTTTC CGCGATGGTAAGAGTGAGGA 
Mcp1 TAAAAAACCTGGATCGGAACC
AA 
GCATTAGCTTCAGATTTACGG
GT 
Tnfa CCCTCACACTCAGATCATCTTC
T 
GCTACGACGTGGGCTACAG 
Il1β CCCTGCAGCTGGAGAGTGTG
GA 
TGTGCTCTGCTTGTGAGGTG
CTG 
Cd36 ATGGGCTGTGATCGGAACTG GTCTTCCCAATAAGCATGTCT
CC 
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Locus 
1 
CACAAAGAGGAAGACCAG TACTGACAGTGGGACCAT 
Locus 
2 
AAGAGGCTGTCTGATTCC AGCCTAGAGCTGAATGACT 
Locus 
3 
GCTTTGTTGAGTCATCCC CAGGCAACACTAGGCTTT 
Locus 
4 
GGACTGATGTATAGTTCCCC CTATGATCCGTCACACAAC 
Huma
n 
RPL4 GCCTGCTGTATTCAAGGCTC GGTTGGTGCAAACATTTCGG
C 
NRIP
1 TAGCACATTACTGGCCTC CTTGAGGCTCTGCCTGATTT 
UCP1 AGAAGGGCGGATGAAACTCT ATCCTGGACCGTGTCGTA 
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Predicted off-target sites 
(5’à3’)
Off-target (OT) editing
(% of sequences) 
Preadipocytes Adipocytes
sgRNA: ACA GGC TGT TGC CAG CAT GG
OT1:      ACT GGC TGT TGC TAG  AAT GG 0 2
sgRNA: ACA GGC TGT TGC CAG CAT GG
OT2:      CCA GGC TGT GGC CAG CAT GC 0 0
sgRNA: ACA GGC TGT TGC CAG CAT GG
OT3:      ACA GGC TGT TGC CTG CTT  TG 0 0
Predicted off-target sites 
(5’à3’)
Off-target (OT) editing
(% of sequences) 
Preadipocytes Adipocytes
sgRNA: GTC ATG TGC TGC AAG ATT AC 
OT1:      GAC ATG TGC TGA AAG ATT TC 0 0
sgRNA: GTC ATG TGC TGC AAG ATT AC 
OT2:      GCC ATG TGC TCC ATG ATT AC 0 0
sgRNA: GTC ATG TGC TGC AAG ATT AC
OT3:      GTT GTG TGC TGC TAG ATT AA 7 0
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